Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L

Monica Bodogai, Catalina Lee Chang, Katarzyna Wejksza, Jinping Lai, Maria Merino, Robert P. Wersto, Ronald E. Gress, Andrew C. Chan, Charles Hesdorffer, Arya Biragyn

Research output: Contribution to journalArticle

Abstract

The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo-targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20Low tBregs. Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B-expressing cytolytic CD8+ T cells, offering some explanative power for the effect. hese findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo.

Original languageEnglish (US)
Pages (from-to)2127-2138
Number of pages12
JournalCancer Research
Volume73
Issue number7
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

Regulatory B-Lymphocytes
Anti-Idiotypic Antibodies
B-Lymphocytes
Neoplasms
Neoplasm Metastasis
Breast Neoplasms
Granzymes
Oligonucleotides
Immune System
Up-Regulation
T-Lymphocytes
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. / Bodogai, Monica; Chang, Catalina Lee; Wejksza, Katarzyna; Lai, Jinping; Merino, Maria; Wersto, Robert P.; Gress, Ronald E.; Chan, Andrew C.; Hesdorffer, Charles; Biragyn, Arya.

In: Cancer Research, Vol. 73, No. 7, 01.04.2013, p. 2127-2138.

Research output: Contribution to journalArticle

Bodogai, M, Chang, CL, Wejksza, K, Lai, J, Merino, M, Wersto, RP, Gress, RE, Chan, AC, Hesdorffer, C & Biragyn, A 2013, 'Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L', Cancer Research, vol. 73, no. 7, pp. 2127-2138. https://doi.org/10.1158/0008-5472.CAN-12-4184
Bodogai, Monica ; Chang, Catalina Lee ; Wejksza, Katarzyna ; Lai, Jinping ; Merino, Maria ; Wersto, Robert P. ; Gress, Ronald E. ; Chan, Andrew C. ; Hesdorffer, Charles ; Biragyn, Arya. / Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. In: Cancer Research. 2013 ; Vol. 73, No. 7. pp. 2127-2138.
@article{b425e1f5cc1e463a85c9164d275014ac,
title = "Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L",
abstract = "The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo-targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20Low tBregs. Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B-expressing cytolytic CD8+ T cells, offering some explanative power for the effect. hese findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo.",
author = "Monica Bodogai and Chang, {Catalina Lee} and Katarzyna Wejksza and Jinping Lai and Maria Merino and Wersto, {Robert P.} and Gress, {Ronald E.} and Chan, {Andrew C.} and Charles Hesdorffer and Arya Biragyn",
year = "2013",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-12-4184",
language = "English (US)",
volume = "73",
pages = "2127--2138",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L

AU - Bodogai, Monica

AU - Chang, Catalina Lee

AU - Wejksza, Katarzyna

AU - Lai, Jinping

AU - Merino, Maria

AU - Wersto, Robert P.

AU - Gress, Ronald E.

AU - Chan, Andrew C.

AU - Hesdorffer, Charles

AU - Biragyn, Arya

PY - 2013/4/1

Y1 - 2013/4/1

N2 - The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo-targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20Low tBregs. Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B-expressing cytolytic CD8+ T cells, offering some explanative power for the effect. hese findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo.

AB - The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo-targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20Low tBregs. Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B-expressing cytolytic CD8+ T cells, offering some explanative power for the effect. hese findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84876008718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876008718&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-4184

DO - 10.1158/0008-5472.CAN-12-4184

M3 - Article

C2 - 23365136

AN - SCOPUS:84876008718

VL - 73

SP - 2127

EP - 2138

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -